Key result
In conscious cynomolgus monkeys, none of the 6 negative compounds prolonged the QTcB interval, whereas 7 of 10 positive compounds significantly prolonged it.
Why the study?
Does oral administration of various drugs prolong the QTcB interval in conscious cynomolgus monkeys?
Does oral administration of various drugs prolong the QTcB interval in conscious cynomolgus monkeys?
In vivo QT assays in conscious cynomolgus monkeys represent a useful model for assessing the risks of drug-induced QT interval prolongation in safety pharmacology studies.
Answers are grounded in this paper and cite their sources.
Supports cynomolgus monkey QTcB assay for preclinical safety screening; leaves open human translation pending clinical validation.
In safety pharmacology studies, the effects on the QT interval of electrocardiograms are routinely assessed using a telemetry system in cynomolgus monkeys. However, there is a lack of integrated databases concerning in vivo QT assays in conscious monkeys. As part of QT Interval Prolongation: Project for Database Construction (QT PRODACT), the present study examined 10 positive compounds with the potential to prolong the QT interval and 6 negative compounds considered to have no such effect on humans. The experiments were conducted at 7 facilities in accordance with a standard protocol established by QT PRODACT. The vehicle or 3 doses of each test compound were administered orally to male cynomolgus monkeys (n=3-4), and telemetry signals were recorded for 24 h. None of the negative compounds prolonged the corrected QT using Bazett's formula (QTcB) interval. On the other hand, almost all of the positive compounds prolonged the QTcB interval, but haloperidol, terfenadine, and thioridazine did not. The failure to detect the QTcB interval prolongation appeared to be attributable for the differences in metabolism between species and/or disagreement with Bazett's formula for tachycardia. In the cynomolgus monkeys, astemizole induced Torsade de Pointes and cisapride caused tachyarrhythmia at lower plasma concentrations than those observed in humans and dogs. These results suggest that in vivo QT assays in conscious monkeys represent a useful model for assessing the risks of drug-induced QT interval prolongation.
No takes yet. Share an insight, caveat, or question.
Ando et al. (2005) studied Drug-induced QT interval prolongation. 16 reference compounds (10 positive, 6 negative) vs. Vehicle was evaluated on QTcB interval prolongation. In conscious cynomolgus monkeys, none of the 6 negative compounds prolonged the QTcB interval, whereas 7 of 10 positive compounds significantly prolonged it.
Synapse has enriched 10 related papers. Consider them for comparative context: